Born the October 25, 1960.

CURRENT POSITION

Full Professor of Internal Medicine at the Department of Clinical and Biological Sciences, University of Turin since 1 December 2016.

Head of the Division of Internal Medicine 1 at the University Hospital San Luigi Gonzaga since 2009.

Deputy Director of the Department of Clinical and Biological Sciences, University of Turin since 2012.

EDUCATION AND PROFESSIONAL EXPERIENCE

MD Degree in Medicine and Surgery cum laude at the University of Turin in 1985.

Postgraduate Specialization in Endocrinology at the University of Turin in 1988.

Assistant Physician at the Division of Internal Medicine of the University Hospital San Luigi Gonzaga, from 1991 to 2001.

Associate Professor of Internal Medicine at the University of Turin from 2001 to 2016.

Head of the Endocrine Laboratory of the Division of Internal Medicine from 2002 to 2009.

RESEARCH EXPERIENCE

His main research areas are: i) the study of peculiar pathophysiologic and clinical features of adrenal tumors, ii) the study of novel diagnostic, prognostic and therapeutic approaches for adrenal cancer patients; iii) the study of peculiar pathophysiologic and clinical features of Cushing's syndrome; iv) the study of the systemic effects of GH and IGF-I in acromegaly.

The first project includes the characterization of incidentally discovered adrenal masses, the definition of diagnostic aspects of subclinical Cushing's syndrome and the assessment of its clinical impact. The second project includes the evaluation of new diagnostic techniques, assessment of prognostic factors and development of advanced therapeutic modalities for adrenal cancer. The third project concerns the study of atypical variants of Cushing's syndrome, the efficacy of specific diagnostic tests, and the assessment of the systemic effects of hypercortisolism. The fourth project concerns the assessment of the clinical consequences of GH and IGF-I excess with particular focus on the relationship between the GH-IGF axis and the neoplastic risk in acromegalic patients.

PUBLICATIONS

148 full papers on peer reviewed international journals. The impact factor of his papers is 617.648, the number of citations is 6402 with h-index 42 (Scopus).

Honors and Memberships

The Endocrine Society and Pharmacia Corporation International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology and Metabolism in 2002 for the paper entitled “Adrenal incidentaloma: a new cause of the metabolic syndrome?” in 2003.

The Endocrine Society International Award for Publishing Excellence in The Journal of Clinical Endocrinology and Metabolism in 2011 for the paper entitled “Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors” in 2012.

Member of the Executive Committee of the “European Network for the Study of Adrenal Tumors – ENS@T” from 2008 to 2013.

Member of the Expert Panel of the European Society of Endocrinology Guidelines on Adrenal Incidentalomas in 2013.

Member of the Endocrine Society, European Society of Endocrinology, European Network for the Study of Adrenal Tumors, Società Italiana di Endocrinologia, Associazione Medici Endocrinologi, Società Italiana di Medicina Interna.

GRANTS

Funds of the University of Turin (ex-60% funds) from 2002 to 2015.

Funds of the Piedmont Region from 2004 to 2009.

Funds of the Italian Ministry of University and Scientific Research (PRIN 2003) as national coordinator of the research project "Role of the GH-IGF-I system on the neoplastic processes in patients with pituitary adenoma” in 2003.

Funds of the Italian Ministry of University and Scientific Research (PRIN 2005) for the research project " GH-IGF-I and risk of colon cancer in patients with acromegaly” as head of local research unit in 2005.

Funds of the Italian Ministry of University and Scientific Research (PRIN 2008) as national coordinator of the research project "Study of molecular markers of diagnostic and prognostic value and development of novel therapeutic strategies for adrenocortical cancer" in 2008.

Funds of the AIFA -Projects of Indipendent Research on Drugs, Orphan Drugs for rare Diseases- as coordinator of the project “"Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-Free Survival in Patients with Adrenocortical Carcinoma at Low-Intermediate Risk of Recurrence” in 2006.

Funds FP-7 of the European Commission -Work Programme "Cooperation-Health-2010-2.4.1-5: Structuring clinical research on adrenal cancers in adults." as principal investigator of the University of Turin in 2011.

Funds of the Italian Ministry of University and Scientific Research (FIRB 2011) as head of local research unit for the project "Study of molecular markers for diagnosis, prognosis and development of novel therapeutic strategies for adrenocortical cancer" in 2012.

Funds of the Associazione Italiana per la Ricerca sul Cancro (AIRC) for the project "Antisecretory and antineoplastic activity of Abiraterone in adrenocortical carcinoma: a preclinical and clinical study" in 2015.

Peer Reviewer Activity

Member of the Editorial Board of “The Journal of Clinical Endocrinology and Metabolism” from 2004 to 2009 and since 2015.

Member of the Editorial Board of “Clinical Endocrinology” since 2009.

Member of Reviewing Committees of The Journal of Clinical Endocrinology and Metabolism, European Journal of Endocrinology, Clinical Endocrinology, Endocrine-Related Cancer.

EXPERIENCE IN CLINICAL TRIALS

European Coordinator of the “First International Randomized Trial in locally advanced and Metastatic Adrenocortical Carcinoma – FIRMACT” from 2004 to 2010.

Study Chair of the international, multicentric trial "Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-Free Survival in Patients with Adrenocortical Carcinoma at Low-Intermediate Risk of Recurrence".

Major scientific accomplishments in the research field

Publication of the paper “Adjuvant mitotane treatment for adrenocortical carcinoma.” (M.

Terzolo, A. Angeli, M. Fassnacht et al., New England Journal of Medicine, 2007; 356: 2372-80). Although retrospective in nature, the study provided the best evidence currently available on the benefit of adjuvant mitotane therapy following radical surgery due to the large patient cohorts and availability of careful matched control groups of untreated patients. The paper is considered a seminal publication that established adjuvant mitotane therapy in the Management of patients with adrenocortical carcinoma.

Publication of the paper “Combination chemotherapy in advanced adrenocortical carcinoma.” (M. Fassnacht, M. Terzolo, B. Allolio et al., New England Journal of Medicine, 2012; 366: 2189-97). The paper reported the results of the first randomized controlled trial ever done in Adrenocortical carcinoma establishing the chemotherapy regimen etoposide, doxorubicin and cisplatin plus mitotane as the standard of treatment for advanced adrenocortical carcinoma.

Coordination of the first randomized controlled trial in adjuvant setting for adrenocortical

carcinoma (ADIUVO study) that was funded by the European Union within the FP-7 program ENS@T CANCER consortium. The study is currently enrolling patients in 6 European Countries and in Canada and is aiming to compare the results of adjuvant mitotane therapy versus no treatment in patients at low risk of recurrence following removal of adrenocortical carcinoma. The study will provide important evidence-based information on the management of patients with adrenocortical carcinoma.